Fbx32抗体;Fbx32 Antibody—艾普蒂 新品

+ +

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of Fbx32 expression in Human skeletal muscle lysate.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:150 dilution.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:150 dilution.    

  
  

The Fbx32 antibody is designed to detect Fbx32. also known as Atrogin-1 or MAFbx (Muscle Atrophy F-box), a key protein involved in ubiquitin-mediated proteolysis. Identified in 2001 as part of the F-box protein family, Fbx32 acts as a substrate-recognition component within the SCF (Skp1-Cullin-F-box) E3 ubiquitin ligase complex. It plays a critical role in targeting specific proteins for degradation via the ubiquitin-proteasome system (UPS), particularly in muscle atrophy.

Fbx32 is upregulated during muscle wasting conditions, such as disuse, fasting, cancer cachexia, or neurodegenerative diseases. It facilitates the degradation of structural and regulatory proteins, including calcineurin and MyoD, disrupting muscle homeostasis. Studies highlight its interaction with signaling pathways like AKT/mTOR; suppressed AKT signaling de-represses FoxO transcription factors, inducing Fbx32 expression. This mechanism links Fbx32 to pathological muscle loss and cardiac hypertrophy.

Antibodies against Fbx32 are widely used in research to study protein turnover, muscle biology, and disease mechanisms. They enable detection of Fbx32 expression via Western blotting, immunohistochemistry, or immunofluorescence, aiding in exploring its role in conditions like muscular dystrophy, sarcopenia, or Alzheimer’s disease. These tools also contribute to therapeutic development, as modulating Fbx32 activity could mitigate atrophy-related pathologies.

Commercial Fbx32 antibodies are typically validated for specificity in human, mouse, or rat samples, with applications in both basic and translational research contexts.